Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| SUMMER INFAN | SUMR | 6.63% |
| RADIANT LOGI | RLGT | 6.38% |
| FEDERAL MOGU | FDML | 5.80% |
| NATUS MEDICA | BABY | 5.34% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
This prompted analysts to revise their estimates higher, sending the stock to a Zacks #2 Rank (Buy).
Based on consensus estimates, analysts project solid earnings growth over the next two years. On top of this, the company pays a dividend that yields 2.5%.
Company Description
Taubman Centers is a real estate investment trust (REIT) focused on shopping centers. The company owns, leases, and/or manages 27 properties throughout the U.S.
It is headquartered in Bloomfield Hills, Michigan and has a market cap of $4.4 billion.
First Quarter Results
Taubman Centers strong first quarter results on April 26. Funds from operation (FFO) per share came in at 75 cents, beating the Zacks Consensus Estimate of 70 cents. It was a 9% increase over the same quarter last year.
Total revenue came in at $169 million, ahead of the consensus of $157 million. This was driven by higher rent and occupancy rates. Leased space at comparable properties increased 150 basis points to 92.0% as average rent per square foot was up 2% to $46.14.
Meanwhile, net operating income (NOI) excluding lease cancellation income increased 9%.
Increased Guidance
Following strong Q1 results, management raised its FFO guidance for 2012 to a range of $3.18-$3.25, up from previous guidance of $3.14 to $3.24. This prompted analysts to revise their estimates higher for both 2012 and 2013, sending the stock to a Zacks #2 Rank (Buy).
The Zacks Consensus Estimate for 2012 is now $3.23, within guidance, and representing 14% growth over 2011 FFO. The 2013 consensus is currently $3.46, corresponding with 7% growth.
Dividend
As a REIT, Taubman Centers must pay out at least 90% of its income to shareholders to avoid paying taxes on that money. This has led to a steady rise in distributions over the last several years:
It currently yields a solid 2.5%.
Valuation
Shares of Taubman Centers aren't cheap, but they're not unreasonable either. The stock trades at 22.3x 12-month forward FFO, a premium to its 10-year median of 15.1x. But considering the strong long-term growth potential, this multiple seems reasonable.
And its enterprise value to EBITDA (earnings before interest, taxes, depreciation and amortization) multiple is 9.2, below the industry median of 12.5 and its 10-year median of 10.6.
The Bottom Line
With rising estimates, strong growth prospects, a 2.5% yield and reasonable valuation, Taubman Centers offers a lot to like.
Todd Bunton is the Growth & Income Stock Strategist for Zacks Investment Research and Editor of the Income Plus Investor service.
Read the full reports :
Analyst Report on TCO